Abbott Receives Health Canada Approval For Xience V Drug Eluting Stent

Abbott has received approval from Health Canada for the Xience V Everolimus Eluting Coronary Stent System, for the treatment of coronary artery disease (CAD).

Reportedly, Xience V is the only drug eluting stent to have demonstrated superiority over the Taxus Paclitaxel-Eluting Coronary Stent System (Taxus) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.

The Xience V drug coated stent is used to treat CAD by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner over time, to help prevent the artery from becoming blocked again following the stent procedure.

Robert Hance, senior vice president of vascular at Abbott, said: Xience V represents a major advancement in the treatment of heart disease, based upon its ease of use and consistently strong performance across all clinical trials.We look forward to launching Xience V immediately in Canada to meet physician demand for this much-awaited drug eluting stent technology.